Parascript receives $244,479.25 federal grant under Affordable Care Act

NewsGuard 100/100 Score

Parascript, LLC, the image analysis and pattern recognition technology provider, today announced that it was awarded a cash grant of $244,479.25 under the U.S. Government's Affordable Care Act. Under this act, the therapeutic discovery project program targets projects that show significant potential to produce new therapies, address unmet medical needs, reduce the long-term growth of health care costs or advance the goal of curing cancer within the next 30 years. The allocation of the credit also reflects which projects show the greatest potential to create and sustain high-quality, high-paying jobs in the United States and to advance the competitiveness in the fields of life, biological, and medical sciences.

"We are very thankful to be recognized by the U.S. government with this grant for our Computer Aided Detection (CAD) software," said Alexander Filatov, president of Parascript. "This grant will help support our ongoing research to help radiologists detect cancers earlier and improve women's health."

Parascript AccuDetect is unique in that it achieves high sensitivity and low false positive rates through the integration of several complementary algorithms and a sophisticated voting scheme within a single CAD system.  AccuDetect is intended to assist radiologists in the early detection of breast cancer during mammography screening exams.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer